Treatment with tenascin C antibody and/or alpha-mangostin reduces tumor growth and lymph node metastasis in a model of metastatic mammary cancer

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591924
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Osaka Health Science University
• Principal Investigator: SHIBATA Masaaki 大阪保健医療大学, 保健医療学部, 教授 (10319543)
• Co-Investigator(Kenkyū-buntansha): KUSAKABE Moriaki (60153277) ; MORIMOTO Junji (90145889)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: テネイシンC抗体 / マンゴスチン / 乳癌 / 転移 / 治療 / マウス / 抗体医薬 / 複合治療

Outline of Final Research Achievements

Metastatic mammary tumors in BALB/c mice were induced by inoculation of syngeneic mammary carcinoma cells into subcutis. These mice were subsequently exposed to 125 microgram tenascin C antibody (TNC Ab) i.p twice weekly, to continuous dietary 4000 ppm alpha-mangostin (MG), or to a combined TNC Ab + MG treatment. Control mice received saline twice weekly i.p. The study was terminated after 6 weeks of agent administration. Tumor volumes were significantly decreased in all treated groups, as were the multiplicities of lymph node and lung metastases. Both TNC Ab and MG also significantly decreased the multiplicity of metastatic foci in any other organ. In conclusion, since lymph node involvement is the most important prognostic factor in breast cancer patients, the anti-metastatic activity of both TNC Ab and MG may be of clinical significance. Unfortunately, the therapeutic effects of TNC Ab and MG were not enhanced by combination in this model.

Free Research Field

乳癌転移抑制